Matoshree Cancer Hospitals Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 2 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 9.02 Cr
- Revenue Growth %
- Profit Growth 57.60%
- Ebitda 61.77%
- Net Worth -13.93%
- Total Assets -7.10%
About Matoshree Cancer Hospitals
Matoshree Cancer Hospitals Private Limited (MCHPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 December 2015 (Nine years and two months 2 days old ). Its registered office is in Kolhapur, Maharashtra, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹9.02 Cr.
Ghansham Kukreja and Laxman Kukreja serve as directors at the Company.
Company Details
-
Location
Kolhapur, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U85100PN2015PTC157565
-
Company No.
157565
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
16 Dec 2015
-
Date of AGM
30 Nov 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Matoshree Cancer Hospitals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ghansham Kukreja
|
Director | 16-Dec-2015 | Current |
|
Laxman Kukreja
|
Director | 16-Dec-2015 | Current |
Financial Performance of Matoshree Cancer Hospitals.
Matoshree Cancer Hospitals Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 57.6% increase in profit. The company's net worth observed a substantial decline by a decrease of 13.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Matoshree Cancer Hospitals?
In 2019, Matoshree Cancer Hospitals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹9.02 Cr
₹0
Charges Breakdown by Lending Institutions
- Others : 9.02 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Feb 2019 | Others | ₹5.16 M | Open |
| 17 Sep 2016 | Others | ₹8.50 Cr | Open |
How Many Employees Work at Matoshree Cancer Hospitals?
Unlock and access historical data on people associated with Matoshree Cancer Hospitals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Matoshree Cancer Hospitals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Matoshree Cancer Hospitals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.